A Randomized Phase II/III Study of TNFerade TM Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer.

Trial Profile

A Randomized Phase II/III Study of TNFerade TM Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2013

At a glance

  • Drugs Golnerminogene pradenovec (Primary) ; Fluorouracil; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms PACT
  • Sponsors GenVec
  • Most Recent Events

    • 22 Jan 2013 Final results published in the Journal of Clinical Oncology.
    • 04 Jun 2012 Primary endpoint 'Overall-survival' has not been met.
    • 04 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top